Relationship of serum uric acid, serum creatinine and serum cystatin C with maternal and fetal outcomes in rural Indian pregnant women

Padma Yalamati¹,*, Aparna Varma Bhongir¹, Kalpana Betha², Ritika Verma¹, and Shailendra Dandge³

¹Department of Biochemistry, SHARE INDIA, Mediciti Institute of Medical Sciences, Ghanpur, Medchal Mandal, R. R. District, Telangana, Hyderabad, India
²Department of Obstetrics & Gynaecology, SHARE INDIA, Mediciti Institute of Medical Sciences, Ghanpur, Medchal Mandal, R. R. District, Telangana, Hyderabad, India
³Department of Pharmacology, SHARE INDIA, Mediciti Institute of Medical Sciences, Ghanpur, Medchal Mandal, R. R. District, Telangana, Hyderabad, India

Abstract

Background—Hypertensive disorders are the most common in pregnancy. Several studies showed a positive correlation between elevated maternal serum uric acid (UA), serum creatinine and adverse maternal and fetal outcomes, but only a few studies are available on serum cystatin C and maternal and fetal outcomes. The present study was undertaken to study the association of serum UA, creatinine and cystatin C with maternal and fetal outcomes.

Methods—Out of 116 pregnant women 69 women had no hypertension and 47 had hypertension with or without proteinuria. Serum UA, creatinine and cystatin C was measured by modified Uricase method, modified kinetic Jaffe’s reaction and particle-enhanced immunonephelometric assay respectively. Multivariate logistic regression was performed to determine the independent effects of serum UA, creatinine and cystatin C on maternal and fetal outcomes using stata 13.1.

Results—The adjusted odds ratio (OR) was 3.73 (95% CI: 1.18-11.75; P=0.024) for UA; 15.79 (95% CI: 3.04-81.94; P=0.001) for creatinine and 2.03 (95% CI: 0.70-5.87; P=0.192) for cystatin C in hypertensive disorders of pregnancy. All the three renal parameters were not significantly associated with birth weight, gestational age of delivery and mode of delivery after adjusting for the confounding factors.

Conclusions—Serum creatinine and uric acid are independent risk factors for hypertensive disorders of pregnancy. High serum uric acid is associated with low birth weight and delivery by caesarian section whereas high serum creatinine with preterm delivery only before adjustment for
confounding factors and not after adjustment. Serum cystatin C was not significantly associated with the maternal and fetal outcomes.

**Keywords**

Uric acid; Creatinine; Cystatin C; Gestational Hypertension; Preeclampsia; Gestational age; Birth weight; Caesarian section; Logistic regression

---

**INTRODUCTION**

Hypertensive disorders account for approximately 2%-10% of all pregnancies.1-2 Among these pre-eclampsia (PE) is one of the major causes of maternal and perinatal morbidity and mortality worldwide whereas uncomplicated gestational hypertension has a better prognosis. Gestational hypertension is defined as the new onset gestational hypertension after the 20th week of gestation but without proteinuria.3 PE is characterized by new onset gestational hypertension after the 20th week of gestation, proteinuria and impaired renal function.3 Due to hormonal and hemodynamic changes of pregnancy, renal function is altered and more so in hypertensive disorders and hence these changes must be considered when assessing renal function in pregnancy. Serum Uric acid (UA), serum creatinine and more recently serum cystatin C levels are the indices of renal function. Several studies have reported a positive correlation between elevated maternal serum UA, serum creatinine and adverse maternal and fetal outcomes.4-10 We found one study showing an association of high plasma cystatin C levels and PE which reflects the acute kidney dysfunction associated with PE but we did not find studies showing the relationship between serum cystatin C and the fetal outcomes.11 We hypothesize that elevated levels of serum UA, serum Creatinine and serum cystatin C are associated with adverse maternal and fetal outcomes and hence in our study we would like to evaluate the relationship between the above mentioned parameters and the maternal and fetal outcomes.

**METHODS**

This pilot study was performed on 116 pregnant women in the Department of obstetrics & gynaecology, Mediciti Institute of Medical Sciences, Ghanpur, Ranga Reddy district, Telangana, India. Written informed consent was taken from all included participants. Among them 69 women did not develop hypertension and 47 developed hypertension with or without proteinuria. All of them had no present or past history of hypertension, diabetes mellitus or renal disease. 5 ml of non-fasting venous blood samples were collected at the time of delivery from all the included participants.10

**Measuring parameters-mother**

The blood pressure was measured using an oscillometric digital sphygmomanometer (Model: Omron HEM-780N3). The international society for the study of hypertension in pregnancy guidelines were followed for the measurement of blood pressure.3 Two measurements taken 4 hours apart with systolic blood pressure ≥140 mm Hg and diastolic blood pressure ≥90 mm Hg was used as the diagnostic criteria for the hypertension in pregnancy. Serum uric acid was measured by modified Uricase method in Dade Behring-
Dimension Xpand plus system using uric acid flex reagent cartridge according to the manufacturer’s instructions. Serum creatinine was measured by modified kinetic Jaffe’s reaction in Dade Behring-Dimension Xpand plus system using creatinine flex reagent cartridge according to the manufacturer’s instructions. Serum cystatin C was measured by a fully automated particle-enhanced immunonephelometric assay (N Latex cystatin C, Dade-Behring, Inc) in BN Pro-Spec nephelometer (Dade Behring, Inc, Deerfield, IL) according to the manufacturer’s instructions. Urinary proteins were measured in random mid-stream urine sample by semi-quantitative dip stick method. Two readings of 1+ (30 mg/dl) were taken as the diagnostic criteria for pre-eclampsia. Further details regarding the methodology were presented previously.

Measuring parameters-new-born

The weight of the new-born was measured by a digital weighing scale (SECA 354/364).

Statistical tools

The data was entered in a MS-Excel database and was analysed using stata 13.1 statistical software (Stata, College Station, Texas USA). We performed multivariate logistic regression to determine the independent effects of serum UA, serum creatinine and serum cystatin C before and after adjusting for the possible confounding factors on maternal and fetal outcomes. The hypertensive disorders of pregnancy, birth weight, gestational age of delivery and mode of delivery were treated as the dependent variables and serum UA, serum creatinine and serum cystatin C as independent variables. Both dependent and independent variables were dichotomized. Hypertension, birth weight and gestational age of delivery were dichotomized using the standard cut-off values. The cut-offs for dichotomization were taken as 5.88 mg/dl for serum uric acid, 0.8 mg/dl for serum creatinine and 1.3 mg/L for serum cystatin C. Serum uric acid ≥5.88 mg/dl, serum creatinine ≥0.8 mg/dl and serum cystatin C ≥1.3 mg/L were coded as 1 and those less than the cut-offs were coded as 0. For each outcome the first model was unadjusted and the second model was adjusted for the covariates as possible confounders in the analysis. The possible confounders were age, BMI, gestational age, parity and birth weight in the first analysis where hypertensive disorders were taken as the dependent variable (Table 2); age, BMI, gestational age, parity and hypertensive disorders in the second analysis where birth weight was taken as the dependent variable (Table 3); age, BMI, parity, birth weight and hypertensive disorders in the third analysis where the gestational age of delivery is the outcome (Table 4); age, BMI, parity, birth weight, gestational age and hypertensive disorders in the fourth analysis where mode of delivery was taken as the dependent variable (Table 5). A p value of <0.05 was considered as statistically significant.

The maternal and child characteristics of the study participants were presented previously in Table 1. The included participants were presently categorized as shown in Table 1.

Table 2 Shows the results of multivariate logistic regression analysis for hypertensive disorders of pregnancy: pregnant women with high serum uric acid (≥5.88 mg/dl) and high serum creatinine (≥0.8 mg/dl) are at over 3.73 times and 15.79 times respectively, the risk of developing hypertensive disorders compared to the pregnant women with low serum uric
acid and low serum creatinine after adjusting for the confounding factors. Hence serum uric acid and serum creatinine are independent risk factors for the development of hypertensive disorders of pregnancy. There was no significant association between serum cystatin C and the development of hypertensive disorders.

Table 3 shows the results of multivariate logistic regression analysis for birth weight: pregnant women having high serum uric acid levels (≥5.88 mg/dl) are at over 2.49 times the risk of giving birth to low birth weight babies (<2.5 Kg) compared to the pregnant women with low serum uric acid before adjusting for the confounding factors but not after adjustment. We found no significant association between serum creatinine, serum cystatin C and the birth weight.

Table 4 shows the results of multivariate logistic regression analysis for gestational age of delivery: pregnant women with high serum creatinine (≥0.8 mg/dl) are at over 3.60 times the risk of having gestational age of delivery < 37 wks. compared to the pregnant women with low serum creatinine before adjusting for the confounding factors but not after adjustment. Serum UA and serum cystatin C were not significantly associated with the gestational age of delivery.

Table 5 shows the results of multivariate logistic regression analysis for mode of delivery: pregnant women with high serum uric acid (≥ 5.88 mg/dl) are at over 2.93 times the risk of undergoing cesarean section compared to the pregnant women with low serum uric acid before adjusting for the confounding factors but not after adjustment. Serum creatinine and serum cystatin C were not significantly associated with the mode of delivery.

**DISCUSSION**

The association between raised serum uric acid and preeclampsia was first reported in 1917. The elevation in serum uric acid and serum creatinine may be attributed to reduced uric acid and creatinine clearance secondary to reduced glomerular filtration rate, increased reabsorption and decreased secretion in women with pre-eclampsia. The pathophysiologic mechanisms of pre-eclampsia comprising increased trophoblastic tissue shedding, endothelial dysfunction, and reduced blood flow in the fetomaternal unit have also been hypothesized as the underlying cause of hyperuricemia in this condition. The elevation in serum cystatin C in pregnancy might be due to increased production due to increase in the number of nucleated cells.

Several studies have reported a positive correlation between elevated maternal serum uric acid levels and adverse maternal and fetal outcomes. There was disagreement in serum uric acid and serum creatinine as predictors of hypertensive disorders. Studies done by weerasekara D.S et al, Manjareeka M et al concluded that serum uric acid and serum creatinine are not predictive of pre-eclampsia and Thangaratinam S et al concluded that serum uric acid is not predictive of preeclampsia. However, Studies done by Roberts et al and Bellomo et al found uric acid to be predictive of gestational hypertension. Our findings of serum uric acid as an independent risk factor for hypertensive disorders of pregnancy agree with the study done by Gianni Bellomo et al and Roberts et al. We did
not observe any significant association between serum cystatin C and the development of hypertensive disorders in contrast to the study done by Franceschini et al.\textsuperscript{11} There are studies to show the association of high serum uric acid levels with the preterm delivery and small for gestational age but in our study we found an association between high serum creatinine (≥0.8 mg/dl) and preterm delivery but not with high serum uric acid and serum cystatin C.\textsuperscript{6,30} Also we found in our study that pregnant women with high uric acid levels (≥5.88 mg/dl) are associated with low birth weight (<2.5 kg) similar to the studies done by Akahori et al, Sagen et al and Schuster et al but serum creatinine and serum cystatin C were not found to be associated with low birth weight.\textsuperscript{31-33} Our findings of high uric acid levels associated with caesarian section agree with the study done by Patel et al.\textsuperscript{30} The variability in the findings can be explained by the differences in the population, definitions of hypertensive disorders of pregnancy and test cut-off values. Our study is limited by the small sample size for each hypertensive disorder group of pregnant women. Also the associations of the three renal parameters with maternal outcomes like the complications of PE and fetal outcomes like Intra Uterine Growth Retardation (IUGR), still births, neonatal deaths, small for gestational age (SGA) and Apgar score have not been studied.

CONCLUSIONS

We have observed that serum creatinine and serum uric acid is independent risk factors for developing hypertensive disorders in pregnant women. High serum uric acid levels are associated with low birth weight and delivery by caesarian section whereas high serum creatinine levels are associated with preterm delivery in pregnant women only before adjustment for confounding factors and not after adjustment. Serum cystatin C was not found to be significantly associated with the studied maternal and fetal outcomes. Further large scale cohort studies are required to study the association between the three renal parameters and all the maternal and fetal outcomes.

ACKNOWLEDGEMENTS

We thank the U.S. National Institutes of Health Fogarty-supported (D43 TW009078) SHARE INDIA and University of Pittsburgh team for conducting the research method courses which contributed to the conduct and publication of this research work. We are very grateful to the nursing staff of the department of Obstetrics & Gynecology and the laboratory technicians for their help in collecting and storing the samples. Also we thank Dr P S Reddy, Chairman, SHARE INDIA, MIMS and Dr Satyanarayana P, Laboratory In charge, MIMS for their support during this work.

Funding: This study was supported by the management of Medicit Institute of Medical Sciences and partly by ICMR Short term studentship (STS) Programme

REFERENCES

1. Matthews Z. World health report 2005: make every mother and child count. World Health. 2005:409–11.
2. American College of Obstetrics and Gynecology. ACOG Practice Bulletin N.33. Diagnosis and management of preeclampsia and eclampsia. Obs Gynecol. 2002; 99:159–67.
3. Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertension in pregnancy: official journal of the International Society for the Study of Hypertension in Pregnancy. 2001:IX–XIV.
4. Redman CW, Beilin LJ, Bonnar J, Wilkinson RH. Plasma-urate measurements in predicting fetal death in hypertensive pregnancy. Lancet. 1976
5. Stone JL, Lockwood CJ, Berkowitz GS, Alvarez M, Lapinski R, Berkowitz RL. Risk factors for severe preeclampsia. Obs Gynecol. 1994; 83(3):357–61.
6. Roberts JM, Bodnar LM, Lain KY, Hubel CA, Markovic N, Ness RB, et al. Uric acid is as important as proteinuria in identifying fetal risk in women with gestational hypertension. 2005; 46(6):1263–9. [PubMed: 16246973]
7. Laughon SK, Catov J, Powers RW, Roberts JM, Gandel J. First trimester uric acid and adverse pregnancy outcomes. Am J Hypertens. 2011; 24(4):489–95. [PubMed: 21252861]
8. Parrish M, Griffin M, Morris R, Darby M, Owens MYMJ. Hyperuricemia facilitates the prediction of maternal and perinatal adverse outcome in patients with severe/superimposed preeclampsia. J Matern Fetal Neonatal Med. 2010; 23:1541–5.
9. Sanders CL, Lucas MJ. Renal disease in pregnancy. Obstetrics and Gynecology Clinics of North America. 2001;593–600. [PubMed: 11512503]
10. Jones DC, Hayslett JP. Outcome of pregnancy in women with moderate or severe renal insufficiency. N Engl J Med. 1996; 335(4):226–32. [PubMed: 8657238]
11. Franceschini N, Qiu C, Barrow DA, Williams MA. Cystatin C and preeclampsia: a case control study. Ren Fail. 2008; 30(1):89–95. [PubMed: 18197549]
12. KALCKAR HM. Differential spectrophotometry of purine compounds by means of specific enzymes; determination of adenine compounds. J Biol Chem. 1947; 167(2):445–9. [PubMed: 20285040]
13. Knapp ML, Mayne PD. Development of an automated kinetic Jaffé method designed to minimise bilirubin interference in plasma creatinine assays. Clin Chim Acta. 1987; 168(2):239–46. [PubMed: 3677419]
14. Finney H, Newman DJ, Gruber W, Merle P, Price CP. Initial evaluation of cystatin C measurement by particle-enhanced immunonephelometry on the behring nephelometer systems (BNA, BN II). Clin Chem. 1997; 43(6):1016–22. [PubMed: 9191555]
15. Johnson, AMRES. Proteins: Analysis of proteins. In: AE, BC., editor. Tietz Fundamentals of Clinical Chemistry. 5th editio. Philadelphia: 2001. p. 350
16. Padma Y, Apana VB, Kalpna B, Ritika V, Sudhakar PR. Renal markers in normal and hypertensive disorders of pregnancy in Indian women: a pilot study. Int J Reprod contraception, Obstet Gynecol. 2013; 2(4):514–20.
17. Khadilkar VV, Khadilkar AV, Choudhry P, Agarwal KN, Ugra D, Shah NK. IAP Growth Monitoring Guidelines for Children from Birth to 18 Years. Indian Pediatr. 2007; 44:187–97. [PubMed: 17413194]
18. Cunningham, FG.; Gant, NF.; Leveno, KJ.; Gilstrap, LC.; Hauth, JCWK. Williams Obstetrics. 21st editi. Mc Graw Hill; New York: 2003. Section VII: Common complications of pregnancy, Preterm birth; p. 690
19. Thangaratinam S, Ismail KMK, Sharp S, Coomarasamy A, Khan KS. Accuracy of serum uric acid in predicting complications of pre-eclampsia: A systematic review. BJOG: An International Journal of Obstetrics and Gynaecology. 2006:369–78. [PubMed: 16553648]
20. Siemons JMBL. The uric acid content of maternal and fetal blood. J Biol Chem. 1917; 32:63–9.
21. Fadel HE, Northrop G, Misenhimer HR. Hyperuricemia in pre-eclampsia. A reappraisal. Am J Obstet Gynecol. 1976; 125(5):640–7. [PubMed: 937388]
22. Chesley LCWLO. Renal glomerular and tubular function in relation to the hyperuricemia of preeclampsia and eclampsia. Am J Obs Gynec. 1945; 50:367–75.
23. Weerasekera DS, Peiris H. The significance of serum uric acid, creatinine and urinary microprotein levels in predicting pre-eclampsia. J Obstet Gynaecol. 2003; 23(1):17–9. [PubMed: 12623475]
24. Many A, Hubel CA, Roberts JM. Hyperuricemia and xanthine oxidase in preeclampsia, revisited. American Journal of Obstetrics and Gynecology. 1996:288–91. [PubMed: 8572024]
25. Liedholm H, Montan S, Aberg A. Risk grouping of 113 patients with hypertensive disorders during pregnancy, with respect to serum urate, proteinuria and time of onset of hypertension. Acta Obst Gynecol Scand Suppl. 1984; 118:43–8. [PubMed: 6587728]
26. Lancet MFI. The value of blood uric acid levels in toxemia of pregnancy. J Obstet Gynaecol Br Emp. 1956; 63:116–9.

27. CN M. An evaluation of the serum uric acid level in pregnancy. J Obstet Gynaecol Br Commonw. 1963; 70:63–8.

28. Manjareeka M, Nanda S. Elevated levels of serum uric acid, creatinine or urea in preeclamptic women. Int J Med Sci Public Heal. 2013; 2(1):43.

29. Bellomo G, Venanzi S, Saronio P, Verdura C, Narducci PL. Prognostic significance of serum uric acid in women with gestational hypertension. Hypertension. 2011; 58(4):704–8. [PubMed: 21876075]

30. Tejpal P, Astha D. Relationship of Serum Uric Acid Level to Maternal and Perinatal Outcome in Patients with Hypertensive Disorders of Pregnancy. 2014; 69(2):1–3.

31. Akahori Y, Masuyama H, Hiramatsu Y. The correlation of maternal uric acid concentration with small-for-gestational-age fetuses in normotensive pregnant women. Gynecol Obstet Invest. 2012; 73(2):162–7. [PubMed: 22301518]

32. Sagen N, Haram KNST. Serum urate as a predictor of fetal outcome in severe pre-eclampsia. Acta Obs Gynecol Scand. 1984; 63(1):71–5.

33. Schuster E, Weppelmann B. Plasma urate measurements and fetal outcome in preeclampsia. Gynecol Obstet Invest. 1981; 12(3):162–7. [PubMed: 7239351]
## Table 1

Categorization of included participants.

| No. | Dependent variable                                      | N  |
|-----|----------------------------------------------------------|----|
| 1   | Blood pressure <140/90 mm Hg                            | 69 |
|     | Blood pressure ≥140/90 mm Hg with or without proteinuria | 47 |
| 2   | Birth weight (Kg) <2.5                                  | 35 |
|     | Birth weight (Kg) ≥2.5                                  | 81 |
| 3   | Gestational age of delivery (wks.) <37                  | 17 |
|     | Gestational age of delivery (wks.) ≥37                  | 99 |
| 4   | Mode of delivery: vaginal                               | 87 |
|     | Mode of delivery: caesarean section                     | 29 |

| Independent variable                          |
|------------------------------------------------|
| 1     | Serum uric acid ≥5.88 mg/dl                       |
|       | Serum uric acid <5.88 mg/dl                       |
| 2     | Serum creatinine ≥0.8 mg/dl                       |
|       | Serum creatinine < 0.8 mg/dl                      |
| 3     | Serum cystatin C ≥1.3 mg/L                        |
|       | Serum cystatin C < 1.3 mg/L                       |
### Table 2

Multivariate logistic regression.

| Parameter                | Model 1 Unadjusted OR (95% CI) | P-value | Model 2 Adjusted OR (95% CI) | P-value |
|--------------------------|-------------------------------|---------|-----------------------------|---------|
| Serum uric acid (mg/dl)  | 2.59 (1.06-6.32)              | 0.036   | 3.73 (1.18-11.75)           | 0.02    |
| Serum creatinine (mg/dl) | 19.93 (4.32-91.88)            | 0       | 15.79 (3.04-81.94)          | 0.00    |
| Serum cystatin C (mg/L)  | 2.34 (0.95-5.76)              | 0.063   | 2.03 (0.70-5.87)            | 0.19    |

* model adjusted for age, BMI, gestational age of delivery, parity & birth weight

** no hypertension coded as 0 and hypertension with or without proteinuria coded as 1

β confidence interval

♦ Statistically Significant (P < 0.05)
Table 3

Multivariate logistic regression.

| Parameter               | Model 1 | Model 2* |
|-------------------------|---------|----------|
|                         | Unadjusted OR (95% CI) | P-value | Adjusted OR (95% CI) | P-value |
| Serum uric acid (mg/dl) | 2.49 (1.01 - 6.17) | 0.047♦ | 1.53 (0.40 - 5.79)   | 0.531   |
| Serum creatinine (mg/dl)| 2.45 (0.89 - 6.72) | 0.08   | 1.58 (0.33 - 7.60)   | 0.565   |
| Serum cystatin C (mg/L) | 1.40 (0.55 - 3.58) | 0.475  | 0.94 (0.25 - 3.51)   | 0.937   |

* model adjusted for age, BMI, gestational age of delivery, parity & blood pressure

# birth weight < 2.5 kg coded as 1 and ≥2.5 kg coded as 0

/β/ confidence interval

♦ Statistically Significant (P < 0.05)
### Table 4

Multivariate logistic regression.

| Parameter                  | Model 1          | Model 2*         |
|----------------------------|------------------|------------------|
|                            | Unadjusted OR    | P-value          | Adjusted OR* | P-value          |
|                            | (95% CI)         |                  | (95% CI)     |                  |
| Serum uric acid (mg/dl)    | 1.54 (0.49 - 4.88) | 0.456            | 0.79 (0.13 - 4.66) | 0.797            |
| Serum creatinine (mg/dl)   | 3.60 (1.13 - 11.43) | 0.029♦          | 1.93 (0.35 - 10.51) | 0.445            |
| Serum cystatin C (mg/L)    | 2.29 (0.75 - 6.99) | 0.143            | 1.97 (0.41 - 9.35) | 0.391            |

* model adjusted for age, BMI, birth weight, parity & blood pressure

δ gestational age of delivery < 37 wks. coded as 1 and ≥37 wks. coded as 0

β confidence interval

♦ Statistically Significant (P < 0.05)
Table 5

Multivariate logistic regression.

| Parameter                  | Model 1                        | Model 2*                       |
|----------------------------|--------------------------------|--------------------------------|
| Serum uric acid (mg/dl)    | Unadjusted OR (95% CI)         | Adjusted OR* (95% CI)         |
|                            | β                              | P-value                        | P-value                        |
|                            | 2.93 (1.15-7.46)               | 2.99 (0.97-9.17)               |
|                            | 0.024*                         | 0.05                           |
| Serum creatinine (mg/dl)   | 1.98 (0.69-5.66)               | 1.13 (0.30-4.18)               |
|                            | 0.198                          | 0.84                           |
| Serum cystatin C (mg/L)    | 2.52 (0.98-6.50)               | 2.46 (0.82-7.42)               |
|                            | 0.055                          | 0.10                           |

* model adjusted for age, BMI, birth weight, parity, blood pressure, gestational age of delivery

£ caesarean section coded as 1 and vaginal delivery coded as 0

β confidence interval

♦ Statistically Significant (P < 0.05)